Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia
| Status: | Completed |
|---|---|
| Conditions: | Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 90 |
| Updated: | 5/5/2014 |
| Start Date: | March 2012 |
| End Date: | March 2016 |
Maintenance Therapy With Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia
This study will determine whether or not Lenalidomide improves effectiveness of treatment
for chronic lymphocytic leukemia following chemotherapy with two drugs commonly used to
treat the disease (bendamustine and rituximab).
for chronic lymphocytic leukemia following chemotherapy with two drugs commonly used to
treat the disease (bendamustine and rituximab).
Inclusion Criteria:
- Previous induction treatment with bendamustine and rituximab
- 18 or more years of age
- chronic lymphocytic leukemia
- ECOG performance status less than or equal to 2
- Absolute neutrophile count more than 1,000
- Platelet count more than 70,000
Exclusion Criteria:
- Serious medical condition that would prevent treatment with lenalidomide
- Evidence of tumor lysis syndrome
- Any prior treatment with lenalidomide
We found this trial at
1
site
Yale Cancer Center Yale Cancer Center combines a tradition of innovative cancer treatment and quality...
Click here to add this to my saved trials
